MedTrace Logo

Lipid Efficacy Study (0524B-022)(COMPLETED)

NCT00269217 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1400

Last updated 2017-04-07

No results posted yet for this study

Summary

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

Conditions

  • Primary Hypercholesterolemia
  • Mixed Hyperlipidemia

Interventions

DRUG

niacin (+) laropiprant (+) simvastatin

Duration of Treatment 12 Weeks

DRUG

Comparator: niacin (+) laropiprant

Duration of Treatment 12 Weeks

DRUG

Comparator: simvastatin

Duration of Treatment 12 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00269217 on ClinicalTrials.gov